TBCR Reading Tools
How to cite item
Efficacy and safety of margetuximab plus chemotherapy
vs
. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study
Citation Format
ABNT
APA
BibTeX
CBE
EndNote - EndNote format (Macintosh & Windows)
MLA
ProCite - RIS format (Macintosh & Windows)
RefWorks
Reference Manager - RIS format (Windows only)
Turabian
@article{{TBCR}{68480}, author = {Zhang, Q., Ouyang, Q., Li, W., Chiu, J., Yan, M., Lu, Y., Sun, S., Li, H., Du, Y., Wang, X., Sun, T., Yin, Y., Wang, H., Ye, F., Shen, K., Wang, J., Pan, Y., Wang, S., Yang, J., Wu, X., Dai, M., Cheng, J., Teng, Y., Su, F., Wu, X., He, J., Fu, P., Yang, L., Xin, Y., Wang, X., Jiang, Z.}, title = {Efficacy and safety of margetuximab plus chemotherapy <em>vs</em>. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study}, journal = {Translational Breast Cancer Research}, volume = {3}, number = {0}, year = {2022}, url = {https://tbcr.amegroups.org/article/view/68480} }